ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
POSTED
07-06-10
ViiV Healthcare Announces Positive Action U.S. Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS
ViiV Healthcare today announced the launch of Positive Action U.S. Southern Initiative, a collaborative, community-focused program designed to address gaps in services or programs that support linkages to care and treatment adherence among individuals living with HIV/AIDS.
POSTED
06-30-10
ViiV Healthcare Awards Grants from the Positive Action for Children Fund of £3.6m
Today ViiV Healthcare awarded a total of £3.6m in grants to support 12 projects focused on preventing HIV transmission from mother-to-child, to improve the health and wellbeing of women, children and their families around the globe. These grants are the first of a series of ...
POSTED
03-22-10
ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund
Today ViiV Healthcare announced the inaugural request for grant proposals (RFPs) through the Positive Action for Children Fund. Over the next ten years, ViiV Healthcare will invest £50 million in the Fund to support programmes focused on preventing HIV transmission from moth...